Treatment of Alzheimer's Disease

Following the discovery of kinom in humans, protein kinases have become the second most important priority in the recovery effort, and therefore can be modulated by small molecule ligands. The role of kinases in the molecular trajectories neurons continue to be studied, but some of the main path has been found. A protein kinase, CK1 and CK2, was found to have a role that has not been known, the molecular pathology of several neurodegenerative disorders, such as Alzheimer's, Parkinson's disease and amyotrophic lateral amiotrofik. Search of specific organic compounds inhibiting this enzyme works in both, now it has become a challenge in the treatment of diseases mentioned above.

Donepezil

Donepezil is a drug taken orally to treat Alzheimer's disease low level to medium. Donepezil is available in oral tablet form. Usually taken once a day before bedtime, before or after meals.

Your doctor will give you a low dose at first and then increased after 4 to 6 weeks. Side effects that often occur while taking donepezil were headache, whole body pain, lethargy, drowsiness, nausea, vomiting, diarrhea, loss of appetite, weight loss, cramps, joint pain, insomnia, and increased frequency of urination.

Rivastigmine

Rivastigmine is a drug taken orally to treat Alzheimer's disease low level to medium. After six months of treatment with Rivastigmine, 25-30% of patients rated improved on tests of memory, understanding, and daily activities than in patients given placebo only 10-20%.

Rivastigmine is usually given twice a day after meals. Because of its side effects on the gastrointestinal tract at the beginning of treatment, treatment with Rivastigmine generally start with a low dose, usually 1.5 mg twice daily, and gradually increased not more than 2 weeks.

The maximum dose is usually up to 6 mg twice daily. If the patient is experiencing indigestion worse because of side effects such as nausea and vomiting, medication should be stopped for a few doses and then continued with the same dose or lower. Approximately half the patients taking Rivastigmine be nausea and vomiting at least once a third, often occurs in the first few weeks of treatment in treatment when the dose increased. Between one-fifth to one quarter of patients experience weight loss during treatment with Rivastigmine (about 7 to 10 pounds).

A sixth patient had a decrease in appetite. One of the fifty patients experiencing dizziness. Overall, 15% of patients (between one-seventh or one-sixth) discontinued treatment due to side effects.

Memantine

Memantin is a drug taken orally to treat diseases Alzhaimer Moderate-to-severe degree by a mechanism distinct and unique keja by improving the process of glutamate signaling. The drug is started with a low dose of 5 mg every week for 3 weeks to achieve the optimal dose of 20 mg / day.

For drug selection dementia or Alzheimer's drug is right it's good you have to consult and consult a doctor.